Oral KVD900 Shows Promise for HAE

Clinical stage pharmaceutical company KalVista Pharmaceuticals (“KalVista”) saw positive data from a Phase 2 clinical trial evaluating its experimental therapy KVD900, shared MedCity News. The Phase 2 trial was exploring KVD900 as a treatment option for patients with hereditary angioedema (HAE). Currently, most FDA-approved drugs associated with HAE are injectable. KalVista’s option, which is orally administered, may offer an easier and more effective treatment option.


After sharing data in a separate press release, it became clear that KVD900 offered significant benefits over a placebo. Additionally, when compared to the current standard-of-care (injectables), KVD900 offered comparable benefits. In the study, which enrolled 68 patients, only 15% of patients needed additional care after 12 hours. Many patients also experienced relief from symptoms associated with HAE attacks in a median 1.6 hours, 7.4 hours less than those taking the placebo. Considering the median time for injectable treatment to kick in is around 1.4 hours, KVD900 offers similar benefits without the additional pain of injectable therapy. The press release also shares that the drug was relatively safe and well-tolerated, with no serious side effects or adverse reactions occurring.

KVD900 works by inhibiting or blocking plasma kallikrein, which helps to regulate and modulate inflammatory responses. Currently, KalVista hopes to plan an additional Phase 3 clinical trial around KVD900 following a meeting with the FDA. Additionally, the company is also developing KVD824, another potential HAE therapy.

Jessica Lynn

Jessica Lynn

Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email